Sulzermedica's sales up 10% in first nine months:
This article was originally published in Clinica
Sulzermedica, the medical arm of Swiss engineering company Sulzer, reported sales of SwFr 845 million ($680 million) in the first nine months, up 10%. Orders were up on the same period in the previous year. Group sales were SwFr 4,153 million, down 2%. The company says that net income for 1996 will be down on last year's figure. This is largely due to damages of $73 million that the company has to pay resulting from a patent infringement lawsuit with Stryker (see Clinica No 726, p 12).
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.